Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01056900
Other study ID # 05CON
Secondary ID
Status Completed
Phase N/A
First received January 21, 2010
Last updated January 24, 2010
Start date December 2008
Est. completion date November 2009

Study information

Verified date January 2010
Source Sewon Cellontech Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority Korea: Food and Drug AdministrationKorea: Institutional Review Board
Study type Observational

Clinical Trial Summary

This investigator-sponsored trial attempts to evaluate the effectiveness of Chondron transplantation by tracking subjects who had the Chondron implantation to observe effectiveness.


Description:

Many treatment cases proved that autologous chondrocyte transplantation is a useful treatment method for patients with damaged articular cartilage.

This investigator-sponsored trial attempts to evaluate the effectiveness of Chondron(autologous chondrocyte) transplantation by tracking subjects who had the Chondron implantation to observe effectiveness.


Recruitment information / eligibility

Status Completed
Enrollment 127
Est. completion date November 2009
Est. primary completion date August 2009
Accepts healthy volunteers No
Gender Both
Age group 15 Years to 65 Years
Eligibility - Inclusion Criteria:

1. Adult males and females aged between 15 and 65

2. Patients with a partial cartilaginous defect in the ankle joint confirmed arthroscopically or visually

3. Patients with misalignment between tibia and talus of the ankle joint, lateral ankle instability, and a bony defect in the cartilaginous defect or who had a correction simultaneously or in advance

4. Patients whose surrounding cartilage is normal

5. Subjects who consented to the clinical trial or on whose behalf a person with parental rights consented to the clinical trial

- Exclusion Criteria:

1. Patients hypersensitive to bovine protein

2. Patients hypersensitive to antibiotics like gentamicin

3. Patients with inflammatory arthritis, such as rheumatoid arthritis and gouty arthritis

4. Patients with arthritis associated with autoimmune diseases

5. Patients who are pregnant, nursing a baby or likely to get pregnant

6. Patients with other diseases including tumors except for cartilaginous defects of joints

7. Patients with an anamnesis within the past two years, such as radiation treatment and chemotherapy

8. Diabetics (however, patients who were normal in the blood glucose test and have no complication due to diabetes will be excluded if the doctor says Chondron can be administered to them)

9. Patients with infections who are taking antibiotics and antimicrobial agents

10. Patients who are treated with adrenal cortical hormones

11. Patients whom the investigators find to be unfit for this clinical trial, such as mental patients

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective


Related Conditions & MeSH terms


Intervention

Procedure:
Autologous Chondrocyte Implantation
Test drug: Chondron (more than 12 million chondrocytes in 0.4ml, i.e. 1 vial) Directions and dosage: Suspend the cells in the vial sufficiently, and implant them in the defective part, making sure that sufficient amounts are injected.

Locations

Country Name City State
Korea, Republic of Sewon Cellontech Sungdong-ku Seoul

Sponsors (1)

Lead Sponsor Collaborator
Sewon Cellontech Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of KSS(Knee Society Score)-A,B pre-operation, post -operation 4month, post-operation 12month, over post-operation 24month. No
Secondary Additional treatment related to autologous chondrocyte implantation post -operation 4month, post-operation 12month, over post-operation 24month. No
Secondary Satisfaction of patients post -operation 4month, post-operation 12month, over post-operation 24month. No